$heff's $tation of $tocks & $olid DD

[rocketeer357]

MACK

from Mike Havrilla: The major risk factor for MACK includes expected failure for several Phase II clinical trials for MM-121 as previously reported and updated in the recent prospectus filing. I believe this is mostly a headline risk since most of the bad news should already be reflected in stock unless the drug fails in every ongoing Phase II trial.

This is a stock which needs little reason to get beat up any more, but it sounds like more reasons might be a comin'.....